Report results from the GRADIENT trial
Delivered after the deadline (122 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 1 Nov 2023
- Due
- 30 Jun 2024
- Delivered
- 30 Oct 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“results expected in mid-2024”
What we found
Evidence strength A What the grades mean
The company announced in July 2024 that GRADIENT trial results were delayed to the fourth quarter of 2024, with positive results ultimately reported on October 30, 2024.
-
A Corcept Therapeutics Inc. 8-K filed 2024-07-29
“results expected in the fourth quarter” ✓ confirmed on the page
-
A Corcept Therapeutics Inc. 8-K filed 2024-10-30
“GRADIENT’s positive results in patients with Cushing’s syndrome confirm relacorilant’s prom” ✓ confirmed on the page
Market reaction: the shares moved +7.4% against the S&P 500 over the three sessions around the disclosure (26 Jul 2024 to 31 Jul 2024). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +184 days
- 2 versions
-
Version 1 · original · stated 1 Nov 2023
Deadline 30 Jun 2024 (“mid-2024”) · wording expected
-
Version 2 · stated 1 May 2024
Deadline 31 Dec 2024 (“by year-end”) · wording expected
“treatment phase results expected by year-end”
-
Version 3 · stated 29 Jul 2024
Deadline 31 Dec 2024 (“the fourth quarter”) · target 137 patients · wording expected
“GRADIENT – Phase 3 trial of relacorilant in 137 patients with Cushing’s syndrome caused by adrenal adenomas – enrollment completed; results expected in the fourth quarter”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout
- Indicative materiality
- Medium rules
- Action
- Report
- Deliverable
- GRADIENT trial results
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Corcept Therapeutics Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-CORT-002883 · Corrections policy